

# TOXICOKINETICS: AN INTEGRAL COMPONENT OF PRECLINICAL TOXICITY STUDIES

SONU SUNDD SINGH

*Nektar Therapeutics India Private Limited, Secunderabad, India*

## Contents

- 1 Introduction
- 2 Objectives of Toxicokinetic Study
- 3 Toxicokinetics in Various Toxicity Studies for Pharmaceuticals
  - 3.1 Safety Pharmacology
  - 3.2 Single Dose-Ranging Toxicity Studies
  - 3.3 Rising Dose Toxicity Studies
  - 3.4 Repeated Dose Toxicity Studies (4 Weeks)
  - 3.5 Repeated Dose Toxicity Studies (6 and 12 Months)
  - 3.6 Genotoxicity Studies
  - 3.7 Carcinogenicity Studies
  - 3.8 Reproductive Toxicity Studies
- 4 Toxicokinetic Evaluation of Biopharmaceuticals
- 5 Factors that Affect the Measurement and Interpretation of Toxicokinetic Data
  - 5.1 Measuring Unbound Versus Bound Drug
  - 5.2 Racemic Compound Versus Enantiomer
  - 5.3 Nonlinear Dose Kinetics
  - 5.4 Measurement of Metabolites
  - 5.5 Measurement of Prodrugs in Biological Fluids and Tissues
  - 5.6 Measurements of Labile Reactive Metabolites
  - 5.7 Human Metabolites that Are Absent in Animal Models
  - 5.8 Species Differences in Pharmacokinetics
  - 5.9 Gender Differences in Pharmacokinetics
  - 5.10 Interpretation of Drug Plasma Concentrations
  - 5.11 Choice of Biological Fluid
  - 5.12 Combination Drugs May Cause Drug–Drug Interactions